What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?
James A. Charles, MD, FAAN, FAHS
Advertisement
Articles by James A. Charles, MD, FAAN, FAHS
Advertisement
Latest Updated Articles
Justifying Use of CGRP mAbs in Pediatric Patients With MigrainePublished: April 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
3
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
4
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
5
